EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Philip J Mease iD, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty iD, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola

ACR Open Rheumatology · 2024-05 · 6 (5) · 304-311

DOI: 10.1002/acr2.11657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 28.02.2024. Verfasst von Philip J Mease und 11 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Research, Providence Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Scientific Affairs, LLC, CorEvitas, LLC, Janssen Scientific Affairs.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Evaluate patient‐reported outcomes after 6 months of on‐label guselkumab use in patients with rheumatologist‐diagnosed active psoriatic arthritis (PsA) enrolled in the CorEvitas PsA/Spondyloarthritis Registry.

Methods

This analysis includes registry participants who initiated and persisted with on‐label guselkumab (after US Food and Drug Administration approval for PsA; 100 mg at weeks 0, 4, and every 8 weeks) at their 6‐month follow‐up visit (On‐Label Persisters). Among patients not meeting response criteria at baseline, responses at 6 months were determined for patient‐reported outcomes, including patient‐reported pain (0–100 mm visual analog scale), patient global assessment of arthritis + psoriasis (PtGA; 0–100 visual analog scale), and Health Assessment Questionnaire‐Disability Index (HAQ‐DI; 0‐3). Unadjusted, nominal P values were calculated via single‐proportion, one‐sided test (H 0 = 0%; α = 0.05).

Results

Of 90 On‐Label Persisters, most had treatment‐resistant PsA (92.2% and 73.3% previously received ≥1 and ≥2 biologic/targeted synthetic disease‐modifying antirheumatic drugs, respectively), with mean (SD) baseline patient‐reported pain, PtGA, and HAQ‐DI scores of 57.0 (24.6), 50.3 (24.4), and 0.9 (0.6), respectively. Among those with patient‐reported pain and PtGA scores of at least 15 at baseline, 40.2% (33/82) and 46.8% (36/77), respectively, achieved at least 15‐mm reductions at 6 months; among those with HAQ‐DI scores of at least 0.35 and more than 0.5 at baseline, respectively, 30.4% (21/69) achieved improvements of at least 0.35 and 10.3% (6/58) achieved scores of 0.5 or lower at 6 months (all nominal P < 0.001).

Conclusion

Pain and physical function are important contributors to health‐related quality of life. In this real‐world population of patients with treatment‐resistant PsA and 6 months of persistent guselkumab treatment, clinically meaningful improvements in pain and physical function were achieved by approximately 40% and 30% of patients, respectively.

Autor:innen und Institutionen

  • Rheumatology Research, Providence Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington.
  • University of Pennsylvania, Philadelphia, Pennsylvania.
  • Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona.
  • Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, and University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.
  • Janssen Scientific Affairs, LLC, Horsham, and Drexel University, Philadelphia, Pennsylvania.

ORCID-Profile: Philip J Mease, Soumya D Chakravarty

Förderung

  • Janssen Scientific Affairs, LLC
  • CorEvitas, LLC
  • Janssen Scientific Affairs

Zitieren

APA

Mease, P. J., Ogdie, A., Tesser, J., Shiff, N. J., Zhao, R. S., Chakravarty, S. D., Kelleman, M., Dodge, R., McLean, R. R., Broadwell, A., Kavanaugh, A., & Merola, J. F. (2024). Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatology, 6(5), 304-311. https://doi.org/10.1002/acr2.11657

Vancouver

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Zhao RS, Chakravarty SD, et al. Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatology. 2024;6(5):304-311. doi:10.1002/acr2.11657

BibTeX
@article{Mease2024,
  author = {Mease, Philip J and Ogdie, Alexis and Tesser, John and Shiff, Natalie J and Zhao, Ruizhi Sophia and Chakravarty, Soumya D and Kelleman, Michael and Dodge, Rhiannon and McLean, Robert R and Broadwell, Aaron and Kavanaugh, Arthur and Merola, Joseph F},
  title = {Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry},
  journal = {ACR Open Rheumatology},
  year = {2024},
  volume = {6},
  number = {5},
  pages = {304--311},
  doi = {10.1002/acr2.11657}
}
Kostenlos starten →